Cambridge Healthtech Institute’s 9th Annual

Engineering Antibody-Drug Conjugates
( 抗体药物复合体工程 )

Innovations for Next-Generation ADCs



By combining the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs, ADCs hold the promise to revolutionize disease treatment, especially for cancer. However, the path toward ADC success is not without challenges. Using lessons learned from the past decade of ADC development, scientists are developing strategies for the third-generation antibody-drug conjugates by selecting the right target antigens, designing new payloads, optimizing linkers and engineering conjugation chemistries.

In this first installment of our 2-part ADC program, PEGS Boston’s 9th Annual Engineering Antibody-Drug Conjugates invites scientists to present their design strategies and share their results in increasing therapeutic window and enhancing ADC internalization.

Coverage will include, but is not limited to:


  • Novel ADC formats
    • Bispecific, biparatopic ADCs
    • Protein scaffolds (DARPins)
    • Nanobodies
    • ScFvs
    • Peptide-drug conjugates
    • Dual-labelled ADCs
    • Radio-immunoconjugates
  • Next-Generation Payloads
    • NAMPT inhibitors
    • KSP inhibitors
    • Glucocorticoids
    • MDR1 inhibitors
  • ADCs Targeting the Tumor Microenvironment
  • Combining ADCs with ImmunoOncology Agents
  • Increasing Therapeutic Window
  • Expanding Target Space
  • Improving Potency and Selectivity
  • Optimizing Linkers and Conjugation Technologies
  • Understanding ADC Metabolism in vivo
  • PKPD Modeling and Simulation
  • ADCs Beyond Oncology

* 活动内容有可能不事先告知作更动及调整。

Choose your language